FDA nod to priority review to AstraZeneca’s Baxdrostat for hard-to-control hypertension
Here's a development that aims to keep your blood pressure in check. Literally!
Here's a development that aims to keep your blood pressure in check. Literally!
The medicine was well tolerated, with no unexpected safety issue
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
Subscribe To Our Newsletter & Stay Updated